Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 9;36(1):3-11.
doi: 10.1515/jbcpp-2024-0140. eCollection 2025 Jan 1.

Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials

Hazem Ayesh  1 , Azizullah Beran  2 , Sajida Suhail  3 , Suhail Ayesh  3 , Kevin Niswender  4
Affiliations
Review

Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials

Hazem Ayesh et al. J Basic Clin Physiol Pharmacol. .

Abstract

Introduction: Metabolic-Associated Steatohepatitis-Related Liver Disease (MASLD) and, its progressive form, Metabolic-Associated Steatohepatitis (MASH) pose significant global health challenges. Current therapeutic strategies targeting metabolic abnormalities have shown promise but lack specificity for the liver. Thyroid hormones, particularly thyroid hormone receptor beta (THR-β) agonists like resmetirom, offer a targeted approach to liver-related pathways.

Content: A network meta-analysis (NMA) comparing different doses of resmetirom to placebo for MASLD and MASH was conducted. PubMed, Scopus, Cochrane, and Web of Science were searched for relevant randomized controlled trials (RCTs). Efficacy outcomes included histological, radiological, and biochemical parameters, while safety outcomes comprised adverse events and treatment discontinuation.

Summary: Resmetirom demonstrated dose-dependent efficacy in histological and radiological assessments, with the 100 mg dose showing superior MASH resolution and hepatic fat reduction. Biochemical markers indicated improved liver function with resmetirom treatment. However, adverse events, particularly diarrhea and nausea, were more prevalent in the resmetirom group, leading to higher treatment discontinuation rates.

Outlook: Resmetirom shows promise as a therapeutic option for MASLD and MASH management, with significant improvements in liver health parameters. However, safety concerns warrant careful monitoring in clinical practice. Further research is needed to optimize its long-term safety and efficacy.

Keywords: MASH; MASLD; THR-β; resmetirom.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Kabarra, K, Golabi, P, Younossi, ZM. Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocr Connect 2021;10:R240–r7. https://doi.org/10.1530/ec-21-0048 . - DOI - PubMed - PMC
    1. Lazure, P, Tomlinson, JW, Kowdley, KV, Magni, P, Santos, RD, Jacobs, G, et al.. Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: an international physician needs assessment. Liver Int 2022;42:1772–82. https://doi.org/10.1111/liv.15324 . - DOI - PubMed - PMC
    1. Jeeyavudeen, MS, Khan, SKA, Fouda, S, Pappachan, JM. Management of metabolic-associated fatty liver disease: the diabetology perspective. World J Gastroenterol 2023;29:126–43. https://doi.org/10.3748/wjg.v29.i1.126 . - DOI - PubMed - PMC
    1. Lee, HA, Kim, HY. Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease. Int J Mol Sci 2023;24:9324. https://doi.org/10.3390/ijms24119324 . - DOI - PubMed - PMC
    1. Li, R, Zhou, L, Chen, C, Han, X, Gao, M, Cheng, X, et al.. Sensitivity to thyroid hormones is associated with advanced fibrosis in euthyroid patients with non-alcoholic fatty liver disease: a cross-sectional study. Dig Liver Dis 2023;55:254–61. https://doi.org/10.1016/j.dld.2022.06.021 . - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources